Following a Phase II review, Novartis has cut the development of a gene therapy candidate for geographic atrophy. In June, the company sold a dry eye disease drug to Bausch + Lomb for $1.75 billion.
Tag Archive for: geographic atrophy
The company scored a regulatory win for its geographic atrophy eye injection Izervay, just three months after the New Jersey biotech was bought by Astellas Pharma for $5.9 billion.
Apellis is speaking to advisers to consider its options and may also seek partnerships or licensing agreements for some of its ophthalmology products, the report said.
Apellis is submitting additional 24-month efficacy data to supplement the NDA for its intravitreal candidate pegcetacoplan for GA secondary to AMD.